
NeoGenomics (NEO) Stock Forecast & Price Target
NeoGenomics (NEO) Analyst Ratings
Bulls say
NeoGenomics is benefiting from a durable shift toward higher-value NGS and MRD testing, with Q3 revenue of about $209M and NGS growth of +29% driving ASPs to $530 per test and lifting gross margin to 48.6% and EBITDA margin to 8.9%. The company’s improving execution is reinforced by repeated top-line beats, raised FY26 guidance to $807M-$809M, and strong cash generation, while the smaller biopharma segment continues to shrink as a share of revenue. Its outlook is further supported by expanding reimbursement for RaDaR ST and PanTracer LBx, which broadens the addressable MRD market and could sustain growth, mix improvement, and margin expansion over time.
Bears say
NeoGenomics is facing a difficult competitive landscape as private specialty labs and other precision oncology rivals gain share through stronger patient data leverage, more advanced NGS reports, and aggressive commercial tactics that can erode legacy testing volumes. Its financial profile also appears fragile, with operations running near breakeven on an Adj. EPS and EBITDA basis, leaving limited margin for error and no assurance of durable profitability. Additional downside comes from potential Medicare pricing cuts, slower innovation versus leading competitors, and execution risk tied to Tempus, where volatile pharma budgets, significant losses since inception, and debt could further pressure growth and sentiment.
This aggregate rating is based on analysts' research of NeoGenomics and is not a guaranteed prediction by Public.com or investment advice.
NeoGenomics (NEO) Analyst Forecast & Price Prediction
Start investing in NeoGenomics (NEO)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About NeoGenomics (NEO) Forecast
NeoGenomics (NEO) Analyst Forecast & Price Prediction
Start investing in NeoGenomics (NEO)
Order type
Buy in
Order amount
Est. shares
0 shares